Every claim, graded against its study.

Decades of work exists on this peptide. Almost nothing an English reader can actually open says a word about human cognition, and I sell the stuff.

I went looking for the human trial I could hand you and came back with mice, a negative result, and one honest reason the Western data is thin.

A three-column test for reading any compound whose evidence sits behind a language border, and what the English-language literature on Semax actually contains.

Semax has a real evidence base, which is exactly what makes it easy to overstate: almost none of it was collected in healthy people at a desk, and almost nobody outside its home research tradition has checked it.

The most convincing sentence in the Semax conversation is a fact about a healthcare system, and buyers keep mistaking it for evidence about a molecule.

The suits are aimed at "research use only", which is the sentence this whole market is built on, including the footer of the shop you buy from.

A reader asked how you sue over a drug nobody is allowed to sell yet. The answer runs through a 2014 Supreme Court case and one word in it: "or".

Four separate regulatory facts get crushed into the word 'legal,' and almost every confident answer online is answering a question you didn't ask.

I sell Semax, and when I followed the claims about it back to their sources, most of them stopped within two clicks. Here's how to tell which ones stop where.

They share a shelf heading, not a mechanism. Here is the four-point test I run before I let the word "versus" into a sentence about two compounds.

They share an address inside the cell and almost nothing else, which is why reading one's evidence into the other will steer you wrong.

The GH-axis peptides are not one evidence base, they're a steep ladder, and the rung most buyers think they're standing on isn't the one they're on.

The prevention result is one of the stronger things in the incretin literature, and the screenshot version of it can't answer any of the three questions that would make it usable.

Five fields decide whether a certificate of analysis describes the vial in your hand or one somebody tested once, two years ago, and you can check all five in thirty seconds.

The claim everyone repeats is factually wrong and directionally right, here's the evidence ladder that settles it in one question.

Two distinct proposed mechanisms, one shared evidence ceiling, and no published study that tested the pair against either compound alone.

Purity tells you the composition of what's in the vial. It says nothing about how much is in there, and almost every certificate published to buyers answers the first question and quietly skips the second.

A new scoping review mapped 80 studies on thymosin beta-4 and TB-500, and exactly one of them studied TB-500 directly. Here's what that does to every claim on the market.